Shots:

• Engitix to receive up front with additional payments based on the confirmation and functional validation of selected targets and is eligible to receive $500M as preclinical- development- regulatory and commercial milestones along with royalties on sales of therapies
• Takeda to get the exclusive rights to develop and commercialize the candidate emerges from the collaboration. The companies will validate the targets and preclinical development of therapeutics in liver fibrosis
• The agreement will focus on developing novel therapies for advanced fibrotic liver diseases- including NASH. The collaboration integrates Engitix’s ECM platform with Takeda’s expertise in gastroenterology R&D and commercialization

­ Ref: PRNewswire | Image:Takeda